The project has received funding from the European Union’s Seventh Framework Programme and aims to develop a non-viral gene therapeutic approach for the treatment of this neurodegenerative disease of the retina

TargetAMD is the acronym of this ambitious project funded by the European Commission in the context of the Seventh Framework Programme and brings together an interdisciplinary team of outstanding scientists from eight European countries. The TargetAMD consortium is developing a novel gene therapy approach to inhibit the neovascularisation and preserve patient’s vision by a long-lasting therapeutic alternative improving significantly the quality of life for patients.

AMD, which is a major cause of blindness in elderly people in developed countries, is a degenerative disease of the retina that damages, in one of its forms, this light sensitive part of the eye by the formation of new blood vessels, which penetrate the retina through Bruch’s membrane.

3P has developed an electroporation buffer that has made great improvement and will be now evaluated for in vitro and in vivo experiments leading to clinical trials. Moreover, the electroporation device which promotes the integration process of the therapeutic gene sequence into the patient cells has been adapted to TargetAMD purposes.

It was the first time the company develops an intermediate product for the electroporation of human cells. The team has the knowledge and the experience to offer this kind of processes to those potential markets that need gene therapy experience.


Cell Therapy Unit

 3P Biopharmaceuticals has a specific Advanced Therapy business unit with high expertise in the manufacturing of cell therapy and tissue engineered products.

The staff in the Cell Therapy Department has broad knowledge and know-how in stem cells from human bone marrow, adipose tissue and somatic cells. They have experience in fields as Ophthalmology, Orthopedia, Cardiology, Oncology, etc.

In April 2014 3P Biopharmaceuticals obtained the GMP (Good Manufacturing Practices) certification for manufacturing process of a cellular medication destined for allergenic therapy treatments. It reinforces 3P’s position in the field of advanced therapy products and its leading in European CMO sector.